feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Nick Reiner killed his parents

trending

Snow causes school delays

trending

Fallout Season 2 release earlier

trending

Sydney Sweeney TikTok hate

trending

SBI cuts FD interest rates

trending

Arizona revokes Underdog's license

trending

New flu variant spreads

trending

High wind warning issued

trending

PA Lottery winning tickets sold

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Pregnancy SSRI Debate: Fear vs. Fact

Pregnancy SSRI Debate: Fear vs. Fact

14 Dec

•

Summary

  • FDA panel raised concerns about SSRIs in pregnancy.
  • Experts say claims link drugs to birth defects are unfounded.
  • Untreated maternal depression poses significant risks.
Pregnancy SSRI Debate: Fear vs. Fact

A recent Food and Drug Administration (FDA) panel discussion concerning Selective Serotonin Reuptake Inhibitors (SSRIs) during pregnancy has ignited significant debate and concern among medical professionals and patient advocates. While some panelists voiced apprehension about potential risks such as miscarriage and birth defects, prominent medical associations have strongly refuted these claims, labeling them "outlandish and unfounded."

The controversy highlights a critical issue: the significant number of women experiencing depression and anxiety during or after pregnancy, many of whom do not receive adequate treatment. Experts emphasize that untreated maternal mental health conditions, including suicide, are a leading cause of death, underscoring the importance of accessible and appropriate care, including the use of SSRIs.

Physicians and therapists are concerned that the panel's discussion, coupled with perceived misinformation, will exacerbate the existing stigma surrounding antidepressant use in pregnancy, potentially leading more mothers to avoid necessary treatment. Organizations like the American College of Obstetricians and Gynecologists stress that SSRIs are among the most well-studied medications in pregnancy and are considered a vital tool for maternal well-being.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
A July FDA panel discussion raised concerns linking SSRIs to increased risks of miscarriage and birth defects, though these claims were widely disputed by medical organizations.
Many medical experts state that SSRIs are generally safe and often life-saving for pregnant women with depression or anxiety, with extensive research supporting their use.
Untreated maternal depression is a leading cause of maternal death and can lead to premature birth, low birth weight, and increased risk of substance misuse and suicide.

Read more news on

Healthside-arrow

You may also like

FDA Expands Libido Pill Access Post-Menopause

15 hours ago • 3 reads

article image

Antidepressant's Hidden Cost: Sex Life Suffers

1 day ago • 7 reads

article image

New Study: Gradual Tapering Cuts Relapse Risk

11 Dec • 23 reads

article image

FDA Proposes Catch-Up for US Sunscreen Standards

12 Dec • 26 reads

article image

FDA Lifts Hormone Therapy Warnings: A New Era for Menopause Relief

5 Dec • 35 reads

article image